- Differential Diagnosis
Drug Information for DARAPRIM (pyrimethamine) 25-mg Scored Tablets (GlaxoSmithKline): CLINICAL PHARMACOLOGY
- CLINICAL PHARMACOLOGY
- ADVERSE REACTIONS
- HOW SUPPLIED
- Diseases/Conditions Related to DARAPRIM (pyrimethamine) 25-mg Scored Tablets (GlaxoSmithKline)
- External Links Related to DARAPRIM (pyrimethamine) 25-mg Scored Tablets (GlaxoSmithKline)
Pyrimethamine is well absorbed with peak levels occurring between 2 to 6 hours following administration. It is eliminated slowly and has a plasma half-life of approximately 96 hours. Pyrimethamine is 87% bound to human plasma proteins.
Pyrimethamine is a folic acid antagonist and the rationale for its therapeutic action is based on the differential requirement between host and parasite for nucleic acid precursors involved in growth. This activity is highly selective against plasmodia and Toxoplasma gondii.
Pyrimethamine possesses blood schizonticidal and some tissue schizonticidal activity against malaria parasites of humans. However, the 4-amino-quinoline compounds are more effective against the erythrocytic schizonts. It does not destroy gametocytes, but arrests sporogony in the mosquito.
The action of pyrimethamine against Toxoplasma gondii is greatly enhanced when used in conjunction with sulfonamides. This was demonstrated by Eyles and Coleman1 in the treatment of experimental toxoplasmosis in the mouse. Jacobs et al2 demonstrated that combination of the 2 drugs effectively prevented the development of severe uveitis in most rabbits following the inoculation of the anterior chamber of the eye with toxoplasma.
- Drug Information Provided by National Library of Medicine (NLM).